Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Forns J, Pottegard A, Reinders T, Poblador-Plou B, Morros R, Brandt L, Cainzos-Achirica M, Hellfritzsch M, Schink T, Prados-Torres A, Giner-Soriano M, Hagg D, Hallas J, Cortes J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M, Reutfors J. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019 Apr 15;249:242-52. doi: 10.1016/j.jad.2019.02.010
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Quteineh L, Preisig M, Rivera M, Milaneschi Y, Castelao E, Gholam-Rezaee M, Vandenberghe F, Saigi-Morgui N, Delacretaz A, Cardinaux JR, Willemsen G, Boomsma DI, Penninx BW, Ching-Lopez A, Conus P, Eap CB. Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. J Affect Disord. 2016 Jul;198:43-9. doi: 10.1016/j.jad.2016.03.031
Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R, Haro JM. Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder? J Affect Disord. 2013 Jul;149(1-3):182-8.
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Gonzalez-Pinto A, Vieta E, Reed C, Novick D, Barraco A, Aguado J, Haro JM. Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM). J Affect Disord. 2011 Jun;131(1-3):320-9.
Twiss J, Jones S, Anderson I. Validation of the Mood Disorder Questionnaire for screening for bipolar disorder in a UK sample. J Affect Disord. 2008 Sep;110(1-2):180-4. doi: 10.1016/j.jad.2007.12.235
Navarro P, García-Esteve L, Ascaso C, Aguado J, Gelabert E, Martín-Santos R. Non-psychotic psychiatric disorders after childbirth: prevalence and comorbidity in a community sample. J Affect Disord. 2008 Jul;109(1-2):171-6.
Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord. 2006 Feb 1;90(2-3):217-21.
McKenna SP, Doward LC, Kohlmann T, Mercier C, Niero M, Paes M, Patrick D, Ramirez N, Thorsen H, Whalley D. International development of the Quality of Life in Depression Scale (QLDS). J Affect Disord. 2001 Mar 1;63(1-3):189-99.